IPOX® Associate Muehlbauer commented in Reuters coverage on Doncasters’ $919.3 million U.S. IPO and upcoming NYSE debut, highlighting the aerospace parts maker’s long operating history and recent turnaround. He noted that Doncasters’ nearly 250-year heritage supports its credibility in a demanding industry, but emphasized that the company’s post-2020 ownership change and more than doubled revenue are central to the story. Muehlbauer also pointed to Doncasters’ positioning across defense and AI-related energy demand themes as key drivers of investor interest globally.

IPOX CEO Josef Schuster commented on Safepoint’s decision to withdraw its planned U.S. listing, telling Reuters that the move appeared to reflect company-specific factors rather than weakness in the broader IPO market. The Florida insurer had sought to raise up to $283.3 million after launching its IPO in May. Reuters noted that the withdrawal came as the IPO market continued to regain momentum, with several Florida-based insurers already completing New York listings in 2025, following recent reforms in Florida’s market.

IPOX® CEO Josef Schuster featured on the First Trust ROI Podcast to discuss post-IPO performance trends, renewed activity in the IPO market, and key dynamics shaping new listings. Schuster highlighted IPOX® research on the long-term divergence between IPO winners and underperformers, the role of diversification in post-IPO investing, and opportunities across IPOs, spin-offs, SPACs, and international markets as investor interest in newly public companies continues to strengthen.

IPOX® Associate Muehlbauer commented on Lime’s planned U.S. IPO in Reuters, highlighting the Uber-backed electric bike and scooter operator’s global scale, cash generation, and strong revenue growth as supportive factors for its proposed valuation of up to $1.66 billion. His analysis also noted key market considerations, including seasonality, regulation, asset intensity, and city-level permit exposure, as Lime prepares to list on Nasdaq under the ticker LIME.

IPOX® Associate Muehlbauer was quoted by Reuters on Kardigan’s Nasdaq debut, after the heart drug developer raised $400 million in an upsized IPO. He noted that biotech IPO activity has improved but remains selective, favoring companies with late-stage assets, clear commercialization paths, visible catalysts, or strong backers. In broader commentary shared with Reuters, Muehlbauer said Kardigan’s going-concern warning was not a deal breaker and reflected why the company raised capital, while follow-on offerings remain a possible overhang for investors.